2015-isolates-detected-115.html
DANMAP 2015 3D
116 / 144
danmap 2015 116
resistance
in human clinical bacteria 8. 8.3 pseudomonas
aeruginosa
pseudomonas
aeruginosa
is an opportunistic pathogen of im- munocompromised individuals. p.
aeruginosa
typically infects the pulmonary tract, urinary tract, burns, wounds, and also causes bloodstream infections. it is the most frequent colo- nizer of medical devices (e.g. indwelling catheters). p. aeru- ginosa infection is a serious problem in patients hospitalised with cancer, cystic fibrosis and burns. the case fatality rate in these patients is high. p.
aeruginosa
is intrinsically resistant to the majority of antimicrobial agents. the antimicrobial classes which can be used for treatment include some fluoroquino- lones (e.g. ciprofloxacin and levofloxacin), aminoglycosides (e.g. gentamicin, tobramycin and amikacin), some beta-lactams (piperacillin-tazobactam, ceftazidime, and carbapenems) and colistin. p.
aeruginosa
blood
isolates
obtained from hospitalised patients for p.
aeruginosa
, danmap 2015 includes data from 11 out of 11 departments of clinical microbiology (dcm), covering the total danish population. danmap received data of 443 p. aeru- ginosa
isolates
from blood.
resistance
levels to all the tested antimicrobial agents were not significantly different from the levels in 2014 (figure 8.10). gentamycin stayed at the same level as in 2014 and the increasing trend in
resistance
from 2009 to 2013 did not seem to be sustained. overall the
resistance
profile of the p.
aeruginosa
isolates
from blood has been highly variable both when combining results from all reporting dcm, and when looking at each dcm individually from year to year. this might be explained by natural fluctua- tion in the numbers of
isolates
. the occurrence of
resistance
to fluoroquinolones, carbapenems, ceftazidime and piperacillin/ tazobactam remained at the same level or lower as reported to ears-net 2014 by the nordic countries [ears-net 2014]. meropenem
resistance
was observed for 4,6% (n =20) of the p.
aeruginosa
isolates
in 2015. a danish study of p.
aeruginosa
carbapenem non-susceptible
isolates
from 2011 showed that carbapenemases were present in a minority of the
isolates
(7%) [hansen et al. 2014 microb. drug res. 20: 22-9]. as in previous years, putative carbapenemase producing p. aerugi- nosa
isolates
were sent on a voluntary basis from the dcm to ssi for national surveillance on carbapenemase producing bacteria, including not only
isolates
from bloodstream infec- tions but also from other origins. in 2015, six vim-producing p.
aeruginosa
isolates
were detected from six different patients. furthermore, two ndm-producing p.
aeruginosa
were detected from two patients. [textbox 8.2]. sissel skovgaard and stefan s. olsen figure 8.10.
resistance
(%) in pseudomonas
aeruginosa
blood
isolates
from humans, denmark note: the number (n) in parentheses represents the number of
isolates
tested for susceptibility in 2015 0 1 2 3 4 5 6 7 8 2007 2008 2009 2010 2011 2012 2013 2014 2015 % resistant
isolates
ciprofloxacin (n=420) gentamicin (n=441) ceftazidime (n=439) meropenem (n=437) piperacillin/tazobactam (n=441) danmap 2015
faecium-isolates-faecalis-117.html
